SCHEMBL1879819

SCHEMBL1879819

CC(C#N)c1cccc(-c2ncco2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.41
LTA4H P09960 1/20 0.37
USP9X Q93008 1/20 0.36
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
NOTUM Q6P988 2/20 0.35
BACE1 P56817 2/20 0.34
BACE2 Q9Y5Z0 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
CTSA P10619 1/20 0.33
HPGD P15428 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14209412 0.83 HPGDS (0.46) HPGDSLTA4HNOTUMBACE1BACE2
SCHEMBL1885410 0.76 PTGS1 (0.46) HPGDSPSEN1PSEN2APH1BNCSTN
SCHEMBL3964365 0.76 HPGDS (0.58) HPGDSLTA4HNOTUMBACE1BACE2
SCHEMBL4260357 0.75 PSEN1 (0.43) HPGDSPSEN1PSEN2APH1BNCSTN
SCHEMBL27705669 0.75 PSEN1 (0.43) HPGDSPSEN1PSEN2APH1BNCSTN
SCHEMBL9079901 0.73 CTSK (0.48) MEN1KMT2ACYP11B1CYP11B2CTSK
SCHEMBL16159319 0.72 HPGDS (0.55) HPGDSLTA4HNOTUMBACE1BACE2
SCHEMBL1884956 0.72 VNN1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3098624 0.72 RAB9A (0.51) HPGDSLTA4HNOTUMBACE1HPGD
SCHEMBL14983820 0.71 HPGDS (0.43) HPGDSLTA4HNOTUMBACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939521-B2 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (IT) 2011-05-10 US disclosed
EP-1856031-B1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-25 EP disclosed
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them DOMPE' PHA.R.MA.S.P.A. (IT) 2008-12-18 US disclosed
EP-1856031-A1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2007-11-21 EP disclosed
WO-2006063999-A1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA.S.P.A. (IT) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them C3AR1, C5AR2, C5AR1 HPGDS 109/4885LTA4H 274/4885USP9X 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.